Gastrointestinal Stromal Tumor Market – Opportunities, Share, Growth and Competitive Analysis and Forecast 2029
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Is The Gastrointestinal Stromal Tumor Market Expected To Grow In Terms Of Size?
In recent times, the market for gastrointestinal stromal tumors has seen significant growth. This market is projected to increase from $1.28 billion in 2024 to $1.36 billion in 2025, with a compound annual growth rate (CAGR) of 6.7%. The noticeable growth during the previous period is attributable to factors such as increased cognizance and early diagnosis, the development of targeted treatments, advanced surgical techniques, the creation of personalized medical approaches, and improvements in supportive care.
In the coming years, robust expansion is predicted for the gastrointestinal stromal tumor market. With a Compound Annual Growth Rate (CAGR) of 7.5%, projections forecast a value of $1.82 billion by 2029. Factors contributing to this positive outlook during the forecast period encompass ongoing investigation and drug innovation, an escalation in patient-focused healthcare, the incorporation of precision medicine in medical practice, widened access to targeted treatments, and the broadening of genomic profiling abilities. The forecast period is also set to witness significant trends such as increased cooperation in research and development, advancements in diagnostic technology, collective research and clinical examinations, amplified attention on early detection and diagnosis, and the investigation into combination therapies.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13248&type=smp
What Are The Primary Factors Supporting The Gastrointestinal Stromal Tumor Market Expansion?
The rise in stomach cancer cases is anticipated to stimulate the advancement of the gastrointestinal stromal tumor market. Stomach cancer is characterized by the unchecked proliferation and growth of malignant cells on the stomach’s inner lining. Although gastrointestinal stromal tumors (GISTs) can be found in the stomach, they are not the same as stomach cancer. Patients with GISTs have shown an elevated risk of developing other cancers, such as small bowel adenocarcinoma, when two distinct tumors converge into one. As an example, the American Cancer Society, an experienced organization based in the United States, foresaw approximately 26,890 stomach cancer cases and 10,880 fatalities in the U.S. in January 2024, contributing to 1.5% of all new cancer diagnoses. Consequently, the mounting incidence of stomach cancer is fueling the growth of the gastrointestinal stromal tumor market.
Which Segmentation Categories Are Highlighted In The Gastrointestinal Stromal Tumor Market Analysis?
The gastrointestinal stromal tumormarket covered in this report is segmented –
1) By Treatment Type: Chemotherapy; Targeted Therapy; Other Treatment Types
2) By Indication: Stomach; Small Intestine; Others Indications
3) By End-User: Hospitals; Clinics; Specialized Cancer Treatment Centers; Other End-Users
Subsegments:
1) By Chemotherapy: Traditional Chemotherapy Agents; Combination Chemotherapy Regimens
2) By Targeted Therapy: Tyrosine Kinase Inhibitors; Other Targeted Agents
3) By Other Treatment Types: Surgery; Radiation Therapy; Clinical Trials For Novel Therapies
Which Trends Are Likely To Redefine Growth Paths In The Gastrointestinal Stromal Tumor Market?
Leading businesses in the gastrointestinal stromal tumor market are producing innovative drugs like QINLOCK (Ripretinib) to appeal to a wider consumer base, raise their sales, and grow their profits. QINLOCK (Ripretinib) is a prescribed medication for advanced gastrointestinal stromal tumor (GIST). For instance, the US Food and Drug Administration (FDA), a federal agency in the US, noted in January 2024, that there were an increase in CDER novel drug approvals from 37 in 2022 to 55 in 2023. Furthermore, out of the 55 new drugs approved in 2023, CDER recognized 20 (or 36%) as being the first of their kind.
Which Organizations Are At The Forefront Of The Gastrointestinal Stromal Tumor Market?
Major companies operating in the gastrointestinal stromal tumor market report are Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., NATCO Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Boston Biomedical Inc., DNAtrix Inc., Advenchen Laboratories LLC, Arog Pharmaceuticals Inc., AB Sciences S.A.
Access The Complete Report Here:
Which Geographic Regions Are Creating Strong Demand In The Gastrointestinal Stromal Tumor Market?
North America was the largest region in the gastrointestinal stromal tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal stromal tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=13248&type=smp
Browse Through More Reports Similar to the Global Gastrointestinal Stromal Tumor Market 2025, By The Business Research Company
Tumor Ablation Therapy Devices Global Market Report 2025
Tumor Embolization Devices Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report
Cancer Tumor Profiling Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
